Lipids Health Prime Time™: Episode 2 Expert Opinions on the Role of Nonstatin Therapies: Exploring the Evidence for New and Emerging Nonstatin Options

Released On
November 30, 2021

Expires On
November 30, 2022

Media Type

Completion Time
45 minutes

Cardiology, Primary Care

Cardiovascular Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the National Lipid Association. Paradigm Medical Communications, LLC is the educational partner.

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)
  • Nurses — 0.75 Contact Hours
  • Pharmacists — 0.75 contact hours (0.075 CEUs)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of cardiologists and primary care physicians, including lipid specialists, internists, family physicians, pharmacists, nurses, nurse practitioners, and PAs.

Program Overview

This fast-paced news broadcast features expert discussions about incorporating new and emerging nonstatin therapies for the lowering of low-density lipoprotein cholesterol (LDL-C) into clinical practice.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Distinguish among current and emerging nonstatin LDL-C therapies based on unique characteristics and clinical profiles
  • Develop evidence-based treatment plans for at-risk patients who require additional lowering of LDL-C levels beyond statin therapy, considering patient preferences and accessibility/coverage
  • Discuss strategies to improve the knowledge, skills, or performance of the healthcare team



Michelle L. O’Donoghue, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Boston, MA


Joseph J. Saseen, PharmD, CLS, FNLA

President, National Lipid Association
Associate Dean for Clinical Affairs
Department of Clinical Pharmacy
Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine
University of Colorado Anschutz Medical Campus
Aurora, CO

Daniel E. Soffer, MD, FNLA, FACP

University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman School of Medicine at the University of Pennsylvania
University of Pennsylvania  
Philadelphia, PA

Accreditation Statement

CME/CE credit provided by the National Lipid Association

In support of improving patient care, the National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation

The National Lipid Association designates this enduring internet activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation

NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacist Accreditation Statement

Universal Activity Number JA0007192-9999-21-018-H01-P (Knowledge). This Activity has been approved for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.

Nursing Credit Designation

The maximum number of hours awarded for this CE activity is 0.75 contact hours.
For the advanced practice nurse, pharmacotherapy contact hours will be determined on your certificate.

Disclosures of Conflicts of Interest

Michelle L. O’Donoghue, MD, MPH

  • Contracted Research: Amgen Inc; AstraZeneca; Merck & Co, Inc; Novartis
  • Speaker: Amgen Inc; AstraZeneca; Janssen Pharmaceuticals, Inc; Novartis

Joseph J. Saseen, PharmD, CLS, FNLA: Has nothing to disclose

Daniel E. Soffer, MD, FNLA

  • Advisory Board: Akcea Therapeutics
  • Other (content creator): Kaneka Medical America LLC
  • Author: Novartis
  • Consultant: Akcea Therapeutics

Susan Halli Demeter, DNP: Has nothing to disclose

The National Lipid Association and Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Instructions for Participation and Credit

To receive a CME certificate of participation, you should:

  1. Follow instructions to register or log in with your professional information and complete the preactivity assessment
  2. View the online activity in its entirety
  3. Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have 3 opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

There is no fee required for participation in this activity.

Course Viewing Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile):
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:

Technical Support:
If you have any technical problems or playback issues, email us at

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at the end of this activity. The deadline to claim credit is November 30, 2022.

For assistance regarding credit, contact

For pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.

Pharmacists MUST request credit before November 30, 2022. Credit requested after this date will be subject to a fee.

Disclosure of Unlabeled Use and Investigational Products

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through readers’ misunderstanding of content.

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Terms of Use and Privacy Policy   

Privacy Policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/Safeguarding Personal Information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

©2021 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.

Contact Information
If you have any questions or comments, please email us at